MedTrace Logo

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

NCT03887026 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-08-21

No results posted yet for this study

Summary

This is a Phase 2a study to evaluate the efficacy and safety of Norketotifen (NKT) in subjects with allergic rhinitis.

Conditions

  • Allergic Rhinitis
  • Allergic Rhinoconjunctivitis

Interventions

DRUG

Norketotifen

Norketotifen oral capsule

DRUG

Placebo

Placebo oral capsule

Sponsors & Collaborators

  • Emergo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Hazar Awad Granko, RPh, PhD · Emergo Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-05-18
Completion
2019-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03887026 on ClinicalTrials.gov